Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG).

MedStar author(s):
Citation: Research And Practice In Thrombosis And Haemostasis. 1(1):134-137, 2017 Jul.PMID: 30046682Institution: MedStar Washington Hospital Center | Washington Cancer InstituteDepartment: Hematology and Oncology | Medicine/Internal MedicineForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: PubMed-not-MEDLINE -- Not indexedYear: 2017ISSN:
  • 2475-0379
Name of journal: Research and practice in thrombosis and haemostasisAbstract: Delayed onset heparin induced thrombocytopenia (HIT), is characterized by a late nadir due to persistent platelet-activating IgG antibodies. It typically begins or worsens 5 or more days after heparin is discontinued with complications such as thrombosis up to 3 weeks after exposure to heparin.<sup>1-3</sup> In 50% of cases, the platelet count can decrease to very low numbers (<20 000/muL), which is not usual for typical HIT. Here we report 2 cases of post-operative delayed onset HIT manifesting as severe thrombocytopenia that persisted despite cessation of heparin and initiation of argatroban. Key Clinical Question: Is intravenous immunoglulin beneficial in severe refractory delayed-onset HIT?All authors: Cruz AL, DeStefano CB, Doucette K, Fitzpatrick K, Jain NA, Malkovska VFiscal year: FY2018Digital Object Identifier: Date added to catalog: 2018-08-02
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 30046682 Available 30046682

Delayed onset heparin induced thrombocytopenia (HIT), is characterized by a late nadir due to persistent platelet-activating IgG antibodies. It typically begins or worsens 5 or more days after heparin is discontinued with complications such as thrombosis up to 3 weeks after exposure to heparin.<sup>1-3</sup> In 50% of cases, the platelet count can decrease to very low numbers (<20 000/muL), which is not usual for typical HIT. Here we report 2 cases of post-operative delayed onset HIT manifesting as severe thrombocytopenia that persisted despite cessation of heparin and initiation of argatroban. Key Clinical Question: Is intravenous immunoglulin beneficial in severe refractory delayed-onset HIT?

English

Powered by Koha